Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Publication Date	May 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	312
ISBN Number	not applicable
Product Code	GMD04625

Price

£1,605.00
approximately: $2,999 | €2,036

PDF

Order above formats by FAX

Summary

This report is an essential source for in-depth information and data relating to the Australia Drug Delivery Devices devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the Drug Delivery Devices in Australia

Scope

The report provides drug delivery devices information broken down into detailed categories and segments in Australia.
Total revenues, products sold, end users, and average pricing.
Market shares of all the key competitors.
Key pipeline products that are set to shape the market, broken down by sector.
Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
Key mergers and acquisitions, partnerships, private equity investments and IPOs.
Customer, hospitals and physicians data.

Reasons to buy

Gain a strong understanding of the drug delivery devices market in Australia.
Evaluate and compare the attractiveness of the market in the country.
Identify growth segments and opportunities in each industry sector within the country.
Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
Analyze the competitiveness of the market in the country and identify hotspots.
Develop strategies based on the latest product, brand, expansion and research and development news in the country.
Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Content

1 Table Of Contents
1 Table Of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Introduction
- 2.1 What Is This Report About?
- 2.2 Definitions
  - 2.2.1 Drug delivery devices
    - 2.2.1.1 Needle-free Injections
    - 2.2.1.2 Inhalation Systems
    - 2.2.1.3 Infusion Systems
3 Healthcare Sector Review
- 3.1 Healthcare Expenditure
- 3.2 Healthcare Infrastructure
- 3.3 Healthcare Policy
4 Drug Delivery Devices in Australia
- 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
- 4.2 Drug Delivery Devices Overall Volume (2000-2012)
- 4.3 Drug Delivery Devices Company Shares (2005-2006)
5 Inhalation Systems in Australia
- 5.1 Inhalation Systems Overall Revenues (2000-2012)
  - 5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)
  - 5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)
- 5.2 Inhalation Systems Overall Volume (2000-2012)
  - 5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)
  - 5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)
- 5.3 Inhalation Systems Average Price (2000-2012)
  - 5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)
  - 5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)
- 5.4 Inhalation Systems Distribution Share (2005-2006)
- 5.5 Inhalation Systems Company Share (2005-2006)
6 Infusion Systems in Australia
- 6.1 Infusion Systems Overall Revenues (2000-2012)
  - 6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)
  - 6.1.2 Infusion Pumps Overall Revenue (2000-2012)
  - 6.1.3 Syringe Pumps Overall Revenues (2000-2012)
- 6.2 Infusion Systems Overall Volume (2000-2012)
  - 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
  - 6.2.2 Infusion Pumps Overall Volume (2000-2012)
  - 6.2.3 Syringe Pumps Overall Volume (2000-2012)
- 6.3 Infusion Systems Average Price (2000-2012)
  - 6.3.1 Infusion Pumps Average Price (2000-2012)
  - 6.3.2 Syringe Pumps Average Price (2000-2012)
  - 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
- 6.4 Infusion Systems Distribution Share (2005-2006)
- 6.5 Infusion Systems Company Share (2005-2006)
7 AstraZeneca PLC Company Profile
- 7.1 Company Overview
- 7.2 Business Overview
  - 7.2.1 Products
  - 7.2.2 History
- 7.3 Locations And Subsidiaries
- 7.4 Financial Deals Landscape
  - 7.4.1 AstraZeneca Completes $6,900 Million Private Placement
  - 7.4.2 AstraZeneca Acquires MedImmune
  - 7.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
  - 7.4.4 AstraZeneca Acquires Arrow Therapeutics
  - 7.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
  - 7.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
  - 7.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
  - 7.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
  - 7.4.9 Schering Signs An Agreement With AstraZeneca
  - 7.4.10 AstraZeneca Signs An Agreement With Pozen
  - 7.4.11 AstraZeneca Signs An Agreement With Abbott
  - 7.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
  - 7.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
  - 7.4.14 AstraZeneca Acquires A Stake In Protherics
  - 7.4.15 AstraZeneca Signs An Agreement With Targacept
  - 7.4.16 AstraZeneca Signs An Agreement With AtheroGenics
  - 7.4.17 AstraZeneca UK Signs An Agreement With Protherics
  - 7.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
  - 7.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
  - 7.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
  - 7.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
  - 7.4.22 AstraZeneca Completes Private Placement Of $750 million
  - 7.4.23 AstraZeneca Prices EUR750 Million Private Placement
  - 7.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
- 7.5 Recent Developments
  - 7.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
  - 7.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
  - 7.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
  - 7.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
  - 7.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
  - 7.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
  - 7.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
  - 7.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
  - 7.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
8 3M Company Profile
- 8.1 Company Overview
- 8.2 Business Overview
  - 8.2.1 Consumer and Office
    - 8.2.1.1 Overview
    - 8.2.1.2 Capital Expenditure
    - 8.2.1.3 Market View
    - 8.2.1.4 Key Strategies
  - 8.2.2 Display and Graphics
    - 8.2.2.1 Overview
    - 8.2.2.2 Financials
    - 8.2.2.3 Capital Expenditure
    - 8.2.2.4 Market View
    - 8.2.2.5 Key Strategies
  - 8.2.3 Electro and Communications
    - 8.2.3.1 Overview
    - 8.2.3.2 Financials
    - 8.2.3.3 Capital Expenditure
    - 8.2.3.4 Market View
    - 8.2.3.5 Key Strategies
  - 8.2.4 Health Care
    - 8.2.4.1 Overview
    - 8.2.4.2 Financials
    - 8.2.4.3 Capital Expenditure
    - 8.2.4.4 Market View
    - 8.2.4.5 Key Strategies
  - 8.2.5 Industrial and Transportation
    - 8.2.5.1 Overview
    - 8.2.5.2 Financials
    - 8.2.5.3 Capital Expenditure
    - 8.2.5.4 Market View
    - 8.2.5.5 Key Strategies
  - 8.2.6 Safety, Security and Protection Services
    - 8.2.6.1 Overview
    - 8.2.6.2 Financials
    - 8.2.6.3 Capital Expenditure
    - 8.2.6.4 Market View
    - 8.2.6.5 Key Strategies
  - 8.2.7 Products
- 8.3 Value Chain Analysis
  - 8.3.1 Manufacturing
    - 8.3.1.1 In House Manufacturing
  - 8.3.2 Product Development
    - 8.3.2.1 Regulatory Approvals
    - 8.3.2.2 Clinical Trials
    - 8.3.2.3 Research and Development
  - 8.3.3 Sales and Marketing
    - 8.3.3.1 Partnerships and Alliances
    - 8.3.3.2 Licensing Agreements
    - 8.3.3.3 E-distribution
- 8.4 SWOT Analysis
  - 8.4.1 3M Company Strengths
    - 8.4.1.1 Strong performance of Industrial and Transportation segment
    - 8.4.1.2 Focused research and development
    - 8.4.1.3 Decentralized operations
3M Company Weaknesses
- 8.4.1.4 Increased operating costs in the U.S
  - 8.4.1.5 Personal care segment's poor performance
3M Company Opportunities
- 8.4.1.6 Expanding global presence
  - 8.4.1.7 The liquid crystal display
  - 8.4.1.8 Enhancing brand portfolio
3M Company Threats
- 8.4.1.9 Foreign currency fluctuations
  - 8.4.1.10 Increasing cost of raw materials
  - 8.4.1.11 Trend for private labels
- 8.5 Revenue Analysis
  - 8.5.1 Revenue by Segment
  - 8.5.2 Revenue by Geography
- 8.6 Financial and Operational Review
  - 8.6.1 Financial Statements
  - 8.6.2 Financial Ratios
- 8.7 Locations And Subsidiaries
- 8.8 Financial Deals Landscape
  - 8.8.1 3M Canada Acquires Les Entreprises Solumed
  - 8.8.2 3M Acquires Bondo
  - 8.8.3 3M Acquires Lingualcare
  - 8.8.4 3M Acquires Abzil Industria E Comercio
  - 8.8.5 3M Acquires Neo Plast
  - 8.8.6 3M Acquires Assets Of DMS Chile
  - 8.8.7 3M Acquires Business Of Innovative Paper Technologies
  - 8.8.8 3M Acquires Powell
  - 8.8.9 Gen-Probe Signs An Agreement With 3M Company
  - 8.8.10 3M Acquires Acolyte Biomedica
  - 8.8.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp
  - 8.8.12 3M Sells Its Pharmaceutical Business To Meda AB
  - 8.8.13 3M Acquires SoftMed Systems
  - 8.8.14 3M Sells its Pharmaceuticals Business to Graceway
  - 8.8.15 Gen-Probe Signs An Agreement With 3M
  - 8.8.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
  - 8.8.17 3M Acquires Biotrace International
  - 8.8.18 Ekahau Secures $16 Million In Additional Funding
  - 8.8.19 3M Acquires Brontes Technologies
  - 8.8.20 3M acquires Nylonge Corp
  - 8.8.21 3M Signs An Agreement With ClozeX Medical
  - 8.8.22 3M Acquires OMNII Oral Pharmaceuticals
  - 8.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway
  - 8.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB
  - 8.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
  - 8.8.26 3M Acquires Accuspray Application Technologies Inc
  - 8.8.27 3M to acquire Rochford Thompson Equipment
  - 8.8.28 3M To Acquire Aearo Technologies From Permira
  - 8.8.29 Permira To Sell Aearo Technologies To 3M
- 8.9 Recent Developments
  - 8.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
  - 8.9.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
  - 8.9.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
  - 8.9.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
  - 8.9.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year
  - 8.9.6 Nov 12, 2007: 3M Declares Quarterly Dividend
  - 8.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
  - 8.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend
  - 8.9.9 May 08, 2007: 3M Declares Quarterly Dividend
  - 8.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
9 Baxter International Company Profile
- 9.1 Company Overview
- 9.2 Business Overview
  - 9.2.1 BioScience
    - 9.2.1.1 Overview
    - 9.2.1.2 Financials
    - 9.2.1.3 Capital Expenditure
  - 9.2.2 Medication Delivery
    - 9.2.2.1 Overview
    - 9.2.2.2 Financials
    - 9.2.2.3 Capital Expenditure
  - 9.2.3 Renal
    - 9.2.3.1 Overview
    - 9.2.3.2 Financials
    - 9.2.3.3 Capital Expenditure
  - 9.2.4 Products
  - 9.2.5 History
- 9.3 Value Chain Analysis
  - 9.3.1 Manufacturing
    - 9.3.1.1 In House Manufacturing
  - 9.3.2 Product Development
    - 9.3.2.1 Regulatory Approvals
    - 9.3.2.2 Clinical Trials
    - 9.3.2.3 Research and Development
  - 9.3.3 Sales and Marketing
    - 9.3.3.1 Partnerships and Alliances
- 9.4 SWOT Analysis
  - 9.4.1 Baxter International Inc. Strengths
    - 9.4.1.1 Diversified geographic presence
    - 9.4.1.2 Sturdy research and development activities
    - 9.4.1.3 Strong financial performance
  - 9.4.2 Baxter International Inc. Weaknesses
    - 9.4.2.1 High levels of inventory
    - 9.4.2.2 Decline in revenues of medication delivery
    - 9.4.2.3 Reduced capital expenditure
  - 9.4.3 Baxter International Inc. Opportunities
    - 9.4.3.1 Co-developing alliances
    - 9.4.3.2 Increasing End Stage Renal Disease patients
    - 9.4.3.3 FDA approval
  - 9.4.4 Baxter International Inc. Threats
    - 9.4.4.1 Legal proceedings
    - 9.4.4.2 Patent litigation
    - 9.4.4.3 Stringent regulations
- 9.5 Revenue Analysis
  - 9.5.1 Revenue by Segment
  - 9.5.2 Revenue by Geography
- 9.6 Financial and Operational Review
  - 9.6.1 Financial Statements
  - 9.6.2 Financial Ratios
- 9.7 Locations And Subsidiaries
- 9.8 Financial Deals Landscape
  - 9.8.1 Baiyunshan And Baxter Form A Joint Venture In China
  - 9.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
  - 9.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
  - 9.8.4 B. Braun Acquires Renal Therapy Business Of Baxter
  - 9.8.5 Innovata signs a license agreement with Baxter International
  - 9.8.6 Kuros Biosurgery Signs An Agreement With Baxter International
  - 9.8.7 Gambro Signs An Agreement With Baxter
  - 9.8.8 Baxter Healthcare And Gambro Enter Into An Agreement
  - 9.8.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
  - 9.8.10 Baxter International And Kaketsuken Enter Into Agreement
  - 9.8.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
- 9.9 Recent Developments
  - 9.9.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
  - 9.9.2 Dec 18, 2007: Baxter Elects CFO
  - 9.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
  - 9.9.4 Aug 01, 2007: Baxter Elects New Board Director
  - 9.9.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
  - 9.9.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
  - 9.9.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
  - 9.9.8 Nov 28, 2006: Baxter Announces Annual Dividend
  - 9.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
- 9.10 Baxter International Inc. Pipeline Products
  - 9.10.1 Next-Generation Home Hemodialysis Machine
    - 9.10.1.1 Product Overview
    - 9.10.1.2 Product Description
    - 9.10.1.3 Product Status
    - 9.10.1.4 Product Milestone
10 GlaxoSmithKline plc Company Profile
- 10.1 Company Overview
- 10.2 Business Overview
  - 10.2.1 Products
  - 10.2.2 History
- 10.3 Locations And Subsidiaries
- 10.4 Financial Deals Landscape
  - 10.4.1 GlaxoSmithKline Acquires CNS
  - 10.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline
  - 10.4.3 CNS To Merge With GlaxoSmithKline
- 10.5 Recent Developments
  - 10.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007
  - 10.5.2 Feb 07, 2008: Full-year results announcement 2007
  - 10.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance
  - 10.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
  - 10.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
11 Novartis AG Company Profile
- 11.1 Company Overview
- 11.2 Business Overview
  - 11.2.1 Major Products and Services
- 11.3 Locations And Subsidiaries
- 11.4 Financial Deals Landscape
  - 11.4.1 Bayer Schering Pharma Acquires U.S. Biologics Manufacturing Facility From Novartis
  - 11.4.2 Novartis To Acquire Majority Stake In Alcon From Nestle
  - 11.4.3 Novartis to sell Medical Nutrition business unit to Nestl
  - 11.4.4 Nestl to Acquire Novartis Medical Nutrition
  - 11.4.5 Novartis to sell its division Gerber Products Company to Nestle
12 Regulation System
- 12.1 Medical Equipment Approval Process
  - 12.1.1 Classification
  - 12.1.2 Registration and Conformity Assessment
- 12.2 Advertising
- 12.3 Labeling and Packaging
- 12.4 Post-market Surveillance
- 12.5 Registration Fee
13 Pricing and Reimbursement
14 Distribution Structure
15 APPENDIX
- 15.1 Global Markets Direct Research Methodology
- 15.2 Coverage
- 15.3 Secondary Research
- 15.4 Primary Research
- 15.5 Models
- 15.6 Forecasts
- 15.7 Expert Panels
- 15.8 Currency Conversion
- 15.9 Contact Us
- 15.10 Disclaimer
List of Tables
- Table 1: Healthcare Infrastructure in Australia, 2005
- Table 2: Healthcare Personnel in Australia, 2005
- Table 3: Hospital Wards by Specialty in Australia, 2003-2007
- Table 4: Doctors by Specialty in Australia, 2003-2007
- Table 5: Drug Delivery Devices, Australia, Overall Revenues ($ mn), 2000-2012
- Table 6: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 7: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 8: Drug Delivery Devices, Australia, Category Revenues ($ mn), 2000-2012
- Table 9: Drug Delivery Devices, Australia, Category Revenues ($ mn), Historic, 2000-2007
- Table 10: Drug Delivery Devices, Australia, Category Revenues ($ mn), Forecast, 2007-2012
- Table 11: Drug Delivery Devices, Australia, Category Volume (Units), 2000-2012
- Table 12: Drug Delivery Devices, Australia, Category Volume (Units), Historic, 2000-2007
- Table 13: Drug Delivery Devices, Australia, Category Volume (Units), Forecast, 2007-2012
- Table 14: Drug Delivery Devices, Australia, Company Share by Revenue ($ mn), 2005-2006
- Table 15: Inhalation Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 16: Inhalation Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 17: Inhalation Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007
- Table 18: Inhalation Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012
- Table 19: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 20: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 21: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 22: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 23: Inhalation Systems, Australia, Overall Volume (Units), Historic, 2000-2007
- Table 24: Inhalation Systems, Australia, Overall Volume (Units), Forecast, 2007-2012
- Table 25: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007
- Table 26: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012
- Table 27: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007
- Table 28: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012
- Table 29: Metered Dose Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007
- Table 30: Metered Dose Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012
- Table 31: Dry Powder Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007
- Table 32: Dry Powder Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012
- Table 33: Inhalation Systems, Australia, Distribution Share (%), 2005-2006
- Table 34: Inhalation Systems, Australia, Company Share by Revenue ($ mn), 2005-2006
- Table 35: Infusion Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 36: Infusion Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 37: Infusion Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007
- Table 38: Infusion Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012
- Table 39: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 40: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 41: Infusion Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 42: Infusion Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 43: Syringe Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Table 44: Syringe Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Table 45: Infusion Systems, Australia, Overall Volume (Units), Historic, 2000-2007
- Table 46: Infusion Systems, Australia, Overall Volume (Units), Forecast, 2007-2012
- Table 47: Infusion Disposable Sets, Australia, Overall Volume (Units), Historic, 2000-2007
- Table 48: Infusion Disposable Sets, Australia, Overall Volume (Units), Forecast, 2007-2012
- Table 49: Infusion Pumps, Australia, Overall Volume (Units), Historic, 2000-2007
- Table 50: Infusion Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012
- Table 51: Syringe Pumps, Australia, Overall Volume (Units), Historic, 2000-2007
- Table 52: Syringe Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012
- Table 53: Infusion Pumps, Australia, Average Price ($), Historic, 2000-2007
- Table 54: Infusion Pumps, Australia, Average Price ($), Forecast, 2007-2012
- Table 55: Syringe Pumps, Australia, Average Price ($), Historic, 2000-2007
- Table 56: Syringe Pumps, Australia, Average Price ($), Forecast, 2007-2012
- Table 57: Infusion Disposable Sets, Australia, Average Price ($), Historic, 2000-2007
- Table 58: Infusion Disposable Sets, Australia, Average Price ($), Forecast, 2007-2012
- Table 59: Infusion Systems, Australia, Distribution Share by Revenue ($ mn), 2005-2006
- Table 60: Infusion Systems, Australia, Company Share by Revenue ($ mn), 2005-2006
- Table 61: AstraZeneca PLC, Subsidiaries
- Table 61: AstraZeneca PLC, Subsidiaries(Contd..)
- Table 62: 3M Company, SWOT Analysis, 2006
- Table 63: 3M Company, Revenue by Segment, USD Million, 2003-2007
- Table 64: 3M Company, Revenue by Geography, USD Million, 2003-2007
- Table 65: 3M Company, Financial Statements, USD Million, 2003-2007
- Table 66: 3M Company, Financial Ratios, USD Million, 2003-2007
- Table 67: 3M Company, Subsidiaries
- Table 68: Baxter International Inc., SWOT Analysis, 2006
- Table 69: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007
- Table 70: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007
- Table 71: Baxter International Inc., Financial Statements, USD Million, 2003-2007
- Table 72: Baxter International Inc., Financial Ratios, USD Million, 2003-2007
- Table 73: Baxter International Inc., Other Locations
- Table 74: Baxter International Inc., Subsidiaries
- Table 75: GlaxoSmithKline plc, Subsidiaries
- Table 76: Novartis Medical Nutrition, Other Locations
- Table 76: Novartis Medical Nutrition, Other Locations(Contd..)
- Table 77: Conformity Assessment of Medical Devices based Device Class, in Australia, 2007
- Table 78: Fee for Registered Device in Australia, 2007
- Table 79: Fee for Device Clinical Trial in Australia, 2007
- Table 80: Evaluation Fee for High and Low Level Registration of Medical Device in Australia, 2007
- Table 81: Evaluation Fee for Variation Registration of Medical Device in Australia, 2007
- Table 82: Fee for Registration of Listed Devices in Australia, 2007
- Table 83: Fee for Registration of Listed Devices for Export Only in Australia, 2007
- Table 84: Fee for Registration of Included Devices in Australia, 2007
- Table 85: Fee for Initial Conformity Assessment of Medical Device in Australia, 2007
- Table 86: Fee for Medical Device Changes Conformity Assessment in Australia, 2007
- Table 87: Fee for Medical Device Conformity Assessment Surveillance Audit in Australia, 2007
- Table 88: Fee for Medical Device Conformity Assessment Review Certificate in Australia, 2007
- Table 89: Fee for Initial Conformity Assessment of Medical Device Components in Australia, 2007
- Table 90: Fee for Conformity Assessment of Changes in Medical Device Components in Australia, 2007
- Table 91: Fee for Abridged Conformity Assessment of Medical Device Components in Australia, 2007
- Table 92: Fee for Inclusion of Medical Device in the Register in Australia, 2007
- Table 93: Fee for ARTG Inclusion for Medical Device in Australia, 2007
- Table 94: Currency Conversion from USD to Local Currency at 2007 Constant Rate
List of Figures
- Figure 1: Total Healthcare Expenditure in Australia, 2000 - 2005
- Figure 2: Healthcare Financing Framework in Australia, 2007
- Figure 3: Healthcare System in Australia, 2007
- Figure 4: Drug Delivery Devices, Australia, Overall Revenues ($ mn), 2000-2012
- Figure 5: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 6: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 7: Drug Delivery Devices, Australia, Category Revenues ($ mn), 2000-2012
- Figure 8: Drug Delivery Devices, Australia, Category Revenues ($ mn), Historic, 2000-2007
- Figure 9: Drug Delivery Devices, Australia, Category Revenues ($ mn), Forecast, 2007-2012
- Figure 10: Drug Delivery Devices, Australia, Category Volume (Units), 2000-2012
- Figure 11: Drug Delivery Devices, Australia, Category Volume (Units), Historic, 2000-2007
- Figure 12: Drug Delivery Devices, Australia, Category Volume (Units), Forecast, 2007-2012
- Figure 13: Drug Delivery Devices, Australia, Company Share (%), 2006
- Figure 14: Inhalation Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 15: Inhalation Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 16: Inhalation Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007
- Figure 17: Inhalation Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012
- Figure 18: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 19: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 20: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 21: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 22: Inhalation Systems, Australia, Overall Volume (Units), Historic, 2000-2007
- Figure 23: Inhalation Systems, Australia, Overall Volume (Units), Forecast, 2007-2012
- Figure 24: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007
- Figure 25: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012
- Figure 26: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007
- Figure 27: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012
- Figure 28: Metered Dose Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007
- Figure 29: Metered Dose Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012
- Figure 30: Dry Powder Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007
- Figure 31: Dry Powder Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012
- Figure 32: Inhalation Systems, Australia, Distribution Share (%), 2006
- Figure 33: Inhalation Systems, Australia, Company Share by Revenue ($ mn), 2006
- Figure 34: Infusion Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 35: Infusion Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 36: Infusion Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007
- Figure 37: Infusion Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012
- Figure 38: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 39: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 40: Infusion Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 41: Infusion Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 42: Syringe Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007
- Figure 43: Syringe Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012
- Figure 44: Infusion Disposable Sets, Australia, Overall Volume (Units), Historic, 2000-2007
- Figure 45: Infusion Disposable Sets, Australia, Overall Volume (Units), Forecast, 2007-2012
- Figure 46: Infusion Pumps, Australia, Overall Volume (Units), Historic, 2000-2007
- Figure 47: Infusion Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012
- Figure 48: Syringe Pumps, Australia, Overall Volume (Units), Historic, 2000-2007
- Figure 49: Syringe Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012
- Figure 50: Infusion Pumps, Australia, Average Price ($), Historic, 2000-2007
- Figure 51: Infusion Pumps, Australia, Average Price ($), Forecast, 2007-2012
- Figure 52: Syringe Pumps, Australia, Average Price ($), Historic, 2000-2007
- Figure 53: Syringe Pumps, Australia, Average Price ($), Forecast, 2007-2012
- Figure 54: Infusion Disposable Sets, Australia, Average Price ($), Historic, 2000-2007
- Figure 55: Infusion Disposable Sets, Australia, Average Price ($), Forecast, 2007-2012
- Figure 56: Infusion Systems, Australia, Distribution Share (%), 2006
- Figure 57: Infusion Systems, Australia, Company Share (%), 2006
- Figure 58: 3M Company, Value Chain Analysis
- Figure 59: Baxter International Inc., Value Chain Analysis
- Figure 60: Classification of Medical Devices in Australia, 2007
- Figure 61: Classification of Noninvasive Devices in Australia, 2007
- Figure 62: Classification of Invasive Devices in Australia, 2007
- Figure 63: Classification of Invasive Devices in Australia, 2007
- Figure 64: Classification of Active Devices in Australia, 2007
- Figure 65: Classification of Special Medical Devices in Australia, 2007
- Figure 66: Conformity Assessment Procedure for Medical Devices in Australia, 2007
- Figure 67: Global Markets Direct Methodology